January 1, 2022Open Access
View Full PaperNivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
Key Points
Key points are not available for this paper at this time.
Abstract
Background: The phase 1 cohorts (1c+1d) of CheckMate 143 (NCT02017717) evaluated the safety/tolerability and efficacy of nivolumab plus radiotherapy (RT) ± temozolomide (TMZ) in newly diagnosed glioblastoma. Methods: = 30). Primary endpoint was safety/tolerability; secondary endpoint was overall survival (OS). Results: promoter. Conclusions: methylation status were observed.